[ Ed note. The COPE site says, "Liz
provides writing, editing, training and consultancy services for various
pharmaceutical companies (most recently Astra Zeneca, Cephalon, Cordis,
GlaxoSmithKline, Eli Lilly, Janssen-Cilag, Merck Serono, Mundipharma, Norgine,
Novo Nordisk, Sanofi Pasteur and Vifor). ]
Rosenberg: Many conflicts of interest in your book,
including COPE's leadership, are structural and create a closed loop of
misinformation, especially because of the money that Pharma wields. How can
sunlight and transparency ever break through?
Healy : Some colleagues and I are in the process
of fine-tuning a free web site that offers FDA MedWatch data with other crucial
dug information but gets people affected by treatment to report in detail for
perhaps the first time. The site, called RxISK.org, also helps patients file an
adverse event report to US and Canadian authorities, with other countries to
follow. For too long, patients, doctors and pharmacists have been isolated from each other when they encounter
adverse drug events and only Pharma's messages get out. This will help them
communicate directly. END
Pharmageddon
David Healy
University of California Press; 1 edition
Hardcover: 320 pages
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
1
